1	Diagnosing pulmonary tuberculosis using sequence-specific purification of urine cell-free DNA
2	Amy Oreskovic, <sup>a</sup> Nuttada Panpradist, <sup>a</sup> Diana Marangu, <sup>b</sup> M. William Ngwane, <sup>c</sup> Zanele P.
3	Magcaba, <sup>c</sup> Sindiswa Ngcobo, <sup>c</sup> Zinhle Ngcobo, <sup>c</sup> David J. Horne, <sup>d,e</sup> Douglas P.K. Wilson, <sup>c,f</sup> Adrienne
4	E. Shapiro, <sup>d,e</sup> Paul K. Drain, <sup>d,e</sup> # Barry R. Lutz <sup>a</sup> #
5	
6	<sup>a</sup> Department of Bioengineering, University of Washington, Seattle, WA, USA
7	<sup>b</sup> Department of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya
8	<sup>c</sup> Umkhuseli Innovation and Research Management, Pietermaritzburg, South Africa
9	<sup>d</sup> Department of Medicine, University of Washington, Seattle, WA, USA
10	<sup>e</sup> Department of Global Health, University of Washington, Seattle, WA, USA
11	<sup>f</sup> Edendale Hospital, University of KwaZulu-Natal, Pietermaritzburg, South Africa
12	
13	Running head: Sequence-specific purification of tuberculosis urine cfDNA
14	
15	#Address correspondence to Barry R. Lutz (blutz@uw.edu) and Paul K. Drain

16 (pkdrain@uw.edu). These authors share senior authorship.

#### 17 ABSTRACT

Transrenal urine cell-free DNA (cfDNA) is a promising tuberculosis (TB) biomarker, but is 18 challenging to detect because of the short length (<100 bp) and low concentration of TB-19 specific fragments. We aimed to improve the diagnostic sensitivity of TB urine cfDNA by 20 21 increasing recovery of short fragments during sample preparation. We developed a highly sensitive sequence-specific purification method that uses hybridization probes immobilized on 22 23 magnetic beads to capture short TB cfDNA (50 bp) with 91.8% average efficiency. Combined 24 with short-target PCR, the assay limit of detection was  $\leq 5$  copies of cfDNA in 10 mL urine. In a clinical cohort study in South Africa, our urine cfDNA assay had 83.7% sensitivity (95% CI: 71.0– 25 91.5%) and 100% specificity (95% CI: 86.2–100%) for diagnosis of active pulmonary TB when 26 27 using sputum Xpert MTB/RIF as the reference standard. The detected cfDNA concentration was 0.14–2804 copies/mL (median 14.6 copies/mL) and was inversely correlated with CD4 count 28 29 and days to culture positivity. Sensitivity was non-significantly higher in HIV-positive (88.2%) 30 compared to HIV-negative patients (73.3%), and was not dependent on CD4 count. Sensitivity 31 remained high in sputum smear-negative (76.0%) and urine LAM-negative (76.5%) patients. 32 With improved sample preparation, urine cfDNA is a viable biomarker for TB diagnosis. Our assay has the highest reported accuracy of any TB urine cfDNA test to date and has the 33 potential to enable rapid non-sputum-based TB diagnosis across key underserved patient 34 populations. 35

#### 36 INTRODUCTION

Tuberculosis (TB) is the leading cause of global mortality due to infectious disease, with an 37 estimated 10 million cases and 1.4 million deaths in 2019 (1). An estimated 30% of TB cases 38 39 remain undiagnosed or unreported, in part due to limitations in rapid diagnostics (1). Current TB tests rely on sputum samples, which are difficult to collect from people living with HIV, 40 41 severely ill patients, and children, and may not detect extrapulmonary TB (EPTB). Rapid 42 sputum-based tests (e.g., smear microscopy, Xpert MTB/RIF) also have lower sensitivity in these 43 same underserved patient populations, who more often have paucibacillary TB (2–4). A WHO consensus meeting identified a rapid, non-sputum-based test as one of the highest priority 44 target products for TB diagnostics (5). 45

Urine is an attractive alternate sample for TB diagnosis because it is easy to collect and poses 46 minimal transmission risk. In patients with active TB disease, TB-specific cell-free DNA (cfDNA) 47 fragments are released into the blood, a fraction of which are filtered through the kidneys and 48 49 excreted in the urine as transrenal cfDNA (6-8). TB-specific cfDNA has been detected in urine 50 from both HIV-negative and HIV-positive patients with pulmonary TB, but diagnostic sensitivities have been inconsistent (0 – 79%) (8–13). High variability in methodology and 51 subsequent performance across studies have limited the understanding of TB urine cfDNA and 52 hindered its clinical implementation (14, 15). 53

54 Urine cfDNA is a challenging target due to the short length and low concentration of TB-specific 55 fragments. While plasma cfDNA has a peak fragment length of 167 bp, urine cfDNA is more fragmented (7, 16, 17). Recently, new sequencing library preparation methods revealed that 56 very short, formerly-undetectable fragments compose a larger fraction of cfDNA than 57 previously realized (18–21). The majority of urine cfDNA fragments are <100 bp, with peak 58 fragment length ranging from 30 – 110 bp (16, 17, 21, 22). Although the fragment length of TB 59 cfDNA has not yet been characterized, bacterial cfDNA is expected to be especially fragmented 60 61 (peak <60 bp) because it is less protected by DNA-associated proteins (21, 23).

The low to moderate sensitivities reported in previous TB urine cfDNA studies are likely due in
 part to sample preparation and/or amplification methods that are sub-optimal for short urine

cfDNA (6, 14). We hypothesized that we could increase the sensitivity of cfDNA-based TB
diagnosis by improving recovery of short cfDNA during the DNA extraction step. We developed
a highly sensitive sequence-specific purification method that uses DNA probes immobilized on
magnetic beads to extract TB-specific cfDNA via hybridization. By combining sequence-specific
purification with short-target PCR, we can reliably detect ≤5 copies of short (50 bp) cfDNA in 10
mL urine (24).

Here, we determined the diagnostic accuracy of our TB cfDNA assay in clinical urine specimens
for the first time. Our results demonstrate the advantages of our sequence-specific purification
approach, contribute to the growing evidence needed to establish urine cfDNA as a TB
biomarker, and will serve as the foundation for future clinical studies in expanded populations
(*e.g.,* children, individuals with EPTB).

## 75 MATERIALS AND METHODS

76 Study design and participants. Participants were enrolled at Edendale Hospital in

77 Pietermaritzburg, South Africa (approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee, #BE475/18). Adults (≥18 years old) meeting the case definition for 78 79 active pulmonary TB were recruited. As a control group, adults with excluded TB diagnosis and 80 no suspicion for active TB disease were enrolled. A separate healthy control group was enrolled at the University of Washington, Seattle, USA (approved by the University of Washington 81 Institutional Review Board, #48840). Participants were adults (>18 years old) with low risk of TB 82 83 exposure, as defined by birth in a country with low TB risk and no history of diagnosis of latent 84 TB, treatment for active or latent TB, or living with an individual with active TB. All participants provided written informed consent. Samples were de-identified prior to testing at the 85 86 University of Washington where this study was conducted.

Case definitions. TB-positive participants (South Africa) were defined as those with a positive
 sputum Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) result within 5 days of enrollment and
 the presence of one or more TB symptom (fever, night sweats, cough, and weight loss). Patients
 with >72 hours of anti-TB treatment were excluded. TB-negative participants (South Africa) had

a primary diagnosis other than TB and no clinical suspicion for TB. Healthy controls (USA) were
 recruited on a volunteer basis and were not seeking medical care.

93 Clinical data, sputum testing, and urine lipoarabinomannan (LAM) testing. Clinical data were collected for all participants enrolled in South Africa. These included date of birth, gender, 94 weight, height, self-reported TB history, presence of TB symptoms (fever, night sweats, cough, 95 96 weight loss), TB treatment duration, HIV test result, and CD4<sup>+</sup> cell count (for participants living 97 with HIV only). Expectorated sputum was submitted to the South African National Health 98 Laboratory System (NHLS) for confirmatory solid and liquid mycobacterial culture and AFB smear microscopy. Mycobacterial culture was performed at the NHLS Provincial TB Reference 99 Laboratory using Middlebrook 7H11 solid agar medium and the liquid BACTEC mycobacterial 100 101 growth indicator tube (MGIT) 960 system (BD, Franklin Lakes, NJ, USA). Cultures were incubated for up to 42 days. Culture plates were read at 3 and 6 weeks, and *M. tuberculosis* was identified 102 103 from solid or liquid cultures using niacin and nitrate testing. Participants were considered 104 culture-positive with growth from either the solid or liquid culture. Smear microscopy was 105 performed in the NHLS Laboratory at Edendale Hospital on decontaminated samples using both 106 Ziehl-Neelson and Auramine stains and considered positive if either stain revealed AFB. Urine was tested using Alere Determine TB LAM Ag (Abbott Laboratories, Chicago, USA). Collection of 107 108 clinical data, sputum testing, and urine LAM testing were not done for healthy controls enrolled 109 in the USA.

110 Urine collection and storage for cfDNA analysis. Each participant was asked to provide a urine 111 sample upon enrollment. As soon as possible after collection, urine was mixed with EDTA and Tris-HCl pH 7.5 to final concentrations of 25 mM and 10 mM, respectively. Urine was stored in 112 DNA LoBind tubes (Eppendorf, Hamburg, Germany) at -20°C at the collection site until shipping. 113 114 Samples were shipped on dry ice to the University of Washington, where they were stored at 115 -80°C until analysis. Immediately before analysis, urine was thawed at 37°C and centrifuged at 116 8,000g for 5 minutes to pellet cell debris. The cell-free urine supernatant was transferred to 117 new 15 mL DNA LoBind tubes (Eppendorf) and characterized using Fisherbrand 10-SG Urine Reagent Strips (Thermo Fisher Scientific, Waltham, MA, USA) to measure the levels of glucose, 118 bilirubin, ketone, specific gravity, blood, pH, protein, urobilinogen, nitrite, and leukocytes. 119

120 **Purification of TB cfDNA from urine sequence-specific hybridization capture.** Urine (10 mL)

- 121 was analyzed in triplicate for each participant, with individual replicates processed on separate
- 122 days. TB-specific urine cfDNA was extracted using our in-house sequence-specific hybridization
- 123 capture method, as described previously (24). We have published a detailed, user-ready
- 124 protocol at <u>http://dx.doi.org/10.17504/protocols.io.bep4jdqw</u>.
- 125 *Immobilization of capture probes on magnetic beads:* Dynabeads MyOne Streptavidin C1
- 126 (Thermo Fisher) were washed three times with an equal volume of high salt wash buffer (1M
- 127 NaCl, 10 mM Tris-HCl pH 8.0, 0.05% (v/v) Tween-20) and resuspended in an equal volume of
- high salt wash buffer. Dual biotinylated capture probes BP1 and BP2 (Table 1), targeting
- 129 opposite strands of the double-stranded IS6110 target region, were pre-mixed in low-EDTA TE
- buffer to a concentration of 50  $\mu$ M each. 25 pmol of each probe (0.5  $\mu$ L of probe mix) per 50  $\mu$ L
- 131 bead equivalent was added to the beads. The beads were immediately vortexed and rotated for
- 132 15 minutes at room temperature to immobilize capture probes on the beads. The beads were
- 133 washed three times with an equal volume of high salt wash buffer and resuspended in an equal
- 134 volume of high salt wash buffer.
- 135 Sequence-specific capture of TB cfDNA: 2.5 mL of 5 M NaCl (final concentration 1 M), 127  $\mu$ L of
- 136 10% (v/v) Tween-20 (final concentration 0.1%), and 50 μL of prepared beads were added to
- 137 each 10 mL urine sample and gently mixed. The samples were denatured in a heat block set to
- 138 120°C for 15 minutes, so that the urine reached a temperature of >90°C. TB cfDNA was
- 139 hybridized to capture probes by rotation at room temperature for 30 minutes.

140 Washing to remove urine and non-target DNA: Samples were centrifuged for 5 minutes at 5000g to pellet beads. All but 1 mL of supernatant was removed and discarded. Beads were 141 142 resuspended in the remaining supernatant and transferred to 1.5 mL DNA LoBind tubes (Eppendorf). The tubes were placed on an Invitrogen Dynamag-2 magnetic rack (Thermo Fisher) 143 for 1 minute and the remaining supernatant was discarded. The beads were washed twice with 144 1 mL high salt wash buffer and once with 1 mL low salt wash buffer (15 mM NaCl, 10 mM Tris-145 146 HCl pH 8.0). For each wash, the tubes were inverted 10 – 20 times, or until no bead aggregate 147 was left on the tube walls, briefly spun down, and placed on the magnetic rack for 1 minute

before removing the wash buffer. After the final wash step, beads were spun down and anyresidual buffer was removed.

150 *Elution of purified TB cfDNA:* Purified TB cfDNA was eluted using 20 μL of freshly-prepared 20

151 mM NaOH. Beads were mixed with NaOH by vortexing, briefly spun down, and placed on the

- 152 magnetic rack. The eluate was transferred directly to PCR wells and partially neutralized with
- 153 3.5 μL 100 mM HCl.

**Amplification of TB-specific urine cfDNA using short-target PCR.** The entire output ( $\sim 24 \mu$ L) 154 from each 10 mL urine sample was analyzed in a single PCR well. Each 50 µL reaction contained 155 1.25 U OneTaq Hot Start DNA Polymerase (New England Biolabs [NEB, Ipswitch, MA, USA]), 1X 156 OneTag GC Reaction Buffer (NEB; 80 mM Tris-SO<sub>4</sub>, 20 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 mM MgSO<sub>4</sub>, 5% glycerol, 157 158 5% dimethyl sulfoxide, 0.06% IGEPAL CA-630, and 0.05% Tween-20, pH 9.2), 0.8 mM dNTPs 159 (NEB), 0.4X EvaGreen (Biotium, Fremont, CA, USA), 200 nM forward primer (Table 1), and 200 160 mM reverse primer (Table 1). qPCR was carried out in a CFX96 Touch Real-Time PCR Detection 161 System (Bio-Rad Laboratories, Hercules, CA, USA) using an initial incubation period of 94°C for 3 162 minutes, followed by 50 amplification cycles of 94°C for 30 seconds, 64°C for 30 seconds, and  $68^{\circ}$ C for 1 minute. Quantification cycle (C<sub>a</sub>) values were determined using the CFX Maestro 163 software version 1.1 (Bio-Rad Laboratories) at a threshold of 500 RFU and recovered copies 164 were calculated using a standard curve run with each PCR. PCR products were confirmed by 165 166 post-amplification melt curve analysis from 65°C to 95°C in 0.5°C increments every 5 seconds.

167 Table 1: Probe, primer, and target sequences.<sup>a</sup>

Oligo	Sequence
Dual	5'-/52-Bio/AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
biotinylated	
capture probe	
#1 (BP1)	

Dual biotinylated capture probe #2 (BP2) <sup>b</sup>	5'-/52-Bio/AAAAAAAAAAAAAAAAAAAAAAAA
Forward primer	5'- CGAACCCTGCCCAGGTCGA-3'
Reverse primer	5'- GTA+GCAGA+CCTCACCTATGTGT-3'
IS <i>6110</i> target (40 bp)	5'- CGAACCCTGCCCAGGTCG <u>ACACATAGGTGAGGTCTG</u> CTAC-3'
IS <i>6110</i> reverse complement (40 bp)	5'-GTAGCAGACCTCACCTATGTG <u>TCGACCTGGGCAGGG</u> TTCG-3'
Synthetic positive control (50 bp)	5'- CGAACCCTGCCCAGGTCGACA <b>CCATTCA<u>ACACATAGGTGAGGTCTG</u>CTAC-3</b> '
Synthetic positive control reverse complement (50 bp)	5'-GTAGCAGACCTCACCTATG <b>TGTTGAATGG</b> TG <u>TCGACCTGGGCAGGG</u> TTCG-3'

170 introduced to differentiate the synthetic positive control from the endogenous MTB complex-

168

169

specific target sequence (IS*6110*) is bolded. All DNA sequences were ordered HPLC-purified
 from Integrated DNA Technologies (Coralville, IA, USA).

<sup>b</sup> BP2 targets the opposite strand (reverse complement) of the DNA strand targeted by BP1.

174 **Criteria for positive samples.** Criteria for positive samples were set prior to analysis, and the 175 assay operator was blinded to the clinical status of the samples until after processing was complete and sample calls were made. Individual replicates were ruled as positive if ≥1 single-176 177 stranded DNA copy of TB cfDNA was detected and the melt temperature  $(T_m)$  matched that of the expected native TB amplicon (76°C). Individual replicates were ruled as negative if 178 179 insufficient TB cfDNA was detected ( $\leq 1$  copy of single-stranded DNA) and/or the T<sub>m</sub> did not match that of the expected native TB amplicon. A sample was ruled as positive if at least two of 180 181 three replicates, analyzed on different days, were positive based on the above definitions. 182 Samples with zero or one positive replicates were ruled as negative.

PCR primer design, controls, and precautions to prevent false positives. We designed PCR 183 184 primers targeting the insertion sequence IS6110, which is an established target for TB diagnosis present at multiple, variable copy number across ~99% of Mycobacterium tuberculosis complex 185 186 strains (25). Our PCR primers (Table 1) amplify a short 40 bp target within a subregion of IS6110 187 that is conserved and specific to the *Mycobacterium tuberculosis* (MTB) complex (26). To avoid false positives due to nonspecific amplification, we used locked nucleic acid (LNA) bases to 188 precisely match the  $T_m$  of the primers and selected an annealing temperature ( $T_a$ ) slightly above 189 190 the primer T<sub>m</sub> to encourage specific amplification without compromising amplification efficiency. The final primer set and optimized PCR conditions result in an average PCR efficiency 191 of 97.1% (95% CI: 95.7 – 98.6%) and no amplification of no template controls (NTCs) or 10 ng of 192 193 human genomic DNA up to at least 45 cycles. To avoid false positives due to contamination, we 194 maintained good laboratory practices to limit contamination (e.g., separating pre- and post-PCR rooms, regular decontamination of work surfaces and pipettes, sterile filtered pipette tips, 195 aliquoting reagents into single-use volumes). In addition, we designed the synthetic positive 196 197 control (50 bp, used as a spike-in control during extraction and for PCR standard curves) to be 198 amplifiable by the same primer pair but distinguishable from the endogenous TB target 199 sequence (40 bp) by melt analysis (Table 1) so that any potential contamination with the

positive control would not result in false positives. Every experiment included a positive control
 (pooled TB-negative urine spiked with 10<sup>3</sup> copies of double-stranded DNA synthetic positive
 control template [Table 1]) and negative control (water without spiked target) that were run
 throughout the entire extraction process alongside clinical urine samples. PCR NTCs (n=3) were
 also included in each experiment.

205 Statistical analysis. Sensitivity and specificity were calculated using a positive sputum Xpert

206 MTB/RIF result and the presence of one or more TB symptoms as the reference standard. 95%

207 confidence intervals for sensitivity and specificity were calculated using the hybrid

208 Wilson/Brown method. Sensitivities were compared across groups using Fisher's exact test. The

209 detected cfDNA concentration was calculated based on the sample means of cfDNA-positive

samples. Detected cfDNA concentrations were compared across groups using the Mann-

211 Whitney test. Correlations with detected cfDNA concentration were assessed using Spearman's

correlation coefficient. Odds ratios were compared to a value of 1 using Fisher's exact test, with

213 95% confidence intervals determined using the Baptista-Pike method. All statistical analysis was

conducted using GraphPad Prism v8.1.2 (San Diego, CA, USA) with a significance level of 0.05.

215 **RESULTS** 

216 Analytical performance of sequence-specific TB cfDNA assay. An overview of our cfDNA assay

is shown in Fig. 1A-B. Recovery of the spiked-in positive control was 91.8% (95% CI: 75.9 –

218 107.6%) across 15 independent experiments (Fig. 1C).



219

220 Fig. 1: Capture and detection of short cfDNA fragments in urine using sequence-specific 221 purification and short-target PCR. (A) Overview of sequence-specific purification and short-222 target PCR (40 bp) protocol for TB cfDNA. (B) Schematic illustrating details of capture probe 223 design targeting the MTB complex-specific insertion element IS6110. (C) Near complete recovery of short TB-specific DNA spiked into urine using sequence-specific purification. A 224 225 positive control (10<sup>3</sup> copies of 50 bp double-stranded DNA in 10 mL pooled urine) was included 226 throughout each experiment alongside clinical samples. The recovery of the positive control 227 was calculated as a percentage of the input (mean  $\pm$  SD, n=15). Key design features, assay 228 optimization, and additional analytical characterization of our sequence-specific purification 229 method for cfDNA are reported in (24). 230 Study participants. We enrolled 73 participants across two sites: Edendale Hospital in South

Africa (49 TB-positive, 10 TB-negative) and the University of Washington in the USA (14 healthy

232 controls with low risk of TB exposure). Participant demographic and clinical data are

summarized in Table 2.

# 234 Table 2: Summary of study participants.

		TB-positive <sup>a</sup> patients (South Africa)	TB-negative controls (South Africa)	Healthy controls (USA)
Total [n]		49	10	14
Gender [n (%)]	Female	22 (44.9%)	8 (80.0%)	5 (35.7%)
	Male	27 (55.1%)	2 (20.0%)	9 (64.3%)
Age, years		38 (31 – 48)	32 (30.25 –	26.5 (24 –
[median (IQR)]			37.25)	28.75)
Height, m		1.68 (1.65 – 1.70)	1.60 (1.59 – 1.68)	n/a
[median (IQR)]				
Weight, kg		55 (48 – 63)	57 (52 – 70)	n/a
[median (IQR)]				
HIV status [n (%)]	HIV-positive	34 (69.4%)	10 (100.0%)	n/a
	HIV-negative	15 (30.6%)	0 (0.0%)	n/a
CD4 <sup>+</sup> T-cell count		85 (42 – 345)	318 (257 – 746)	n/a
(cells/mm <sup>3</sup> ) <sup>b</sup>				
[median (IQR)]				
History of prior	No	32 (65.3%)	6 (60.0%)	14 (100.0%)
ı B [n (%)]	Yes	17 (34.7%)	4 (40.0%)	0 (0.0%)
	Treatment-naïve	36 (73.5%)	n/a	n/a

TB treatment status [n (%)]	Some treatment <sup>c</sup>	13 (26.5%)	n/a	n/a
TB culture result	Culture-positive	34 (69.4%)	0	n/a
[n (%)]	Culture-negative	8 (16.3%)	9 (90.0%)	n/a
	No culture result	7 (14.3%)	1 (10.0%)	n/a
Days to culture positivity [median (IQR)]		13.5 (8.0 – 17.0)	n/a	n/a
AFB smear result	Smear-positive	19 (38.8%)	0 (0.0%)	n/a
[n (%)]	Smear-negative	25 (51.0%)	5 (50.0%)	n/a
	No smear result	5 (10.2%)	5 (50.0%)	n/a
Alere urine LAM	LAM-positive	15 (30.6%)	0 (0.0%)	n/a
result [n (%)]	LAM-negative	34 (69.4%)	10 (100.0%)	n/a

- <sup>a</sup> TB-positive patients were defined as those with a positive Xpert MTB/RIF result and the
- 236 presence of one or more TB symptoms.
- <sup>b</sup> CD4 count was measured for HIV-positive patients only.
- <sup>c</sup> All participants had  $\leq$ 72 hours of treatment.
- 239 Sensitivity and specificity of sequence-specific TB cfDNA assay. A summary of the diagnostic
- accuracy of our TB urine cfDNA assay is given in Table 3. Full results for each participant,
- 241 including paired clinical data and detected cfDNA concentration, are given in Supplemental
- 242 Dataset S1. Using sputum Xpert MTB/RIF as the reference standard, we detected TB-specific
- 243 urine cfDNA with 83.7% sensitivity (n=41/49; 95% CI: 71.0 91.5%) and 100% specificity

- (n=24/24; 95% CI: 86.2 100%). No TB-specific cfDNA was detected in the urine of TB-negative
   controls in South Africa (n=10) or healthy controls in the USA (n=14).
- 246 Sensitivity was non-significantly higher in HIV-positive patients compared to HIV-negative
- 247 patients (88.2% [n=30/34; 95% CI: 73.4 95.3%] vs. 73.3% [n=11/15; 95% CI: 48.1 89.1%];
- p=0.23). Sensitivity was similar in HIV-positive patients with CD4 counts of  $\leq$ 200 and  $\geq$ 200
- 249 cells/mm<sup>3</sup> (87.5% [n=20/22; 95% CI: 52.1 99.4%] vs. 83.3% [n=10/12; 95% CI: 55.2 97.0%]).
- 250 Sensitivity was 77.8% (n=28/36; 95% CI: 61.9 88.3%) in treatment-naïve patients. If a positive
- 251 sputum culture result was also required for the TB case definition, total sensitivity increased to
- 252 88.2% (n=30/34; 95% CI: 73.4 95.3%). We detected TB-specific cfDNA in the urine of all
- 253 patients with positive AFB sputum smear (n=19/19) and/or Alere urine LAM (n=15/15) results.
- 254 Sensitivity remained high in smear-negative (76.0% [n=19/25; 95% CI: 56.6 88.5%]) and LAM-
- 255 negative (76.5% [n=26/34; 95% CI: 60.0 87.6%]) patients. The reduction in sensitivity for
- smear-negative patients compared to smear-positive patients was significant (p=0.029), while
- that for LAM-negative compared to LAM-positive patients was not (p=0.087). See Table S1 for
- 258 statistical analysis of sensitivity across groups.
- 259 We evaluated factors associated with TB cfDNA positivity and found that only a positive AFB
- smear result was significantly associated with a positive TB cfDNA result (odds ratio >1,
- p=0.029). HIV status, CD4 count, treatment status, culture result, and LAM result were not
- significantly associated with a positive urine cfDNA result (Table S2).
- Table 3: Sensitivity and specificity of TB urine cfDNA assay.

		cfDNA-		cfDNA-	
		positive/	Sensitivity	negative/	Specificity
		<b>TB-positive</b>	(95% CIª) (%)	TB-negative	(95% CIª) (%)
		(n/N)		(n/N)	
Total <sup>b</sup>		41/49	83.7 (71.0 – 91.5)	24/24	100 (86.2 – 100)
HIV status	HIV-positive	30/34	88.2 (73.4 – 95.3)	10/10	100 (72.3 – 100)

	HIV-negative	11/15	73.3 (48.1 – 89.1)	0/0	n/a
CD4⁺ count <sup>c</sup>	≤200 cells/mm³	20/22	87.5 (52.1 – 99.4)	1/1	100 (51.0 – 100)
	>200 cells/mm <sup>3</sup>	10/12	83.3 (55.2 – 97.0)	9/9	100 (70.1 – 100)
Sputum	Positive	30/34	88.2 (73.4 – 95.3)	0/0	n/a
culture result	Negative	6/8	75.0 (40.9 – 95.6)	9/9	100 (70.1 – 100)
AFB sputum	Positive	19/19	100 (83.2 – 100)	0/0	n/a
smear result	Negative	19/25	76.0 (56.6 – 88.5)	5/5	100 (56.6 – 100)
Alere urine	Positive	15/15	100 (79.6 – 100)	0/0	n/a
LAM result	Negative	26/34	76.5 (60.0 – 87.6)	10/10	100 (72.3 – 100)
TB treatment status	Treatment- naïve	28/36	77.8 (61.9 – 88.3)	10/10	100 (72.3 – 100)
	Some treatment <sup>d</sup>	13/13	100 (77.2 – 100)	0/0	n/a
Gender <sup>b</sup>	Female	18/22	81.8 (61.5 – 92.7)	13/13	100 (77.2 – 100)
201101	Male	23/27	85.2 (67.5 – 94.1)	11/11	100 (74.1 – 100)

<sup>a</sup> 95% confidence intervals for sensitivity and specificity were calculated using the hybrid

265 Wilson/Brown method.

<sup>b</sup> Healthy controls enrolled in the USA were included in total specificity and gender-specific

267 specificity, but not in the remaining specificities.

- <sup>c</sup>CD4 count was measured for HIV-positive patients only.
- <sup>d</sup> All participants had  $\leq$ 72 hours of treatment.

Quantification of TB-specific cfDNA concentration in urine. The detected TB-specific cfDNA 270 271 concentration was variable and skewed towards low concentrations, with a median of 146 272 copies in 10 mL urine (Table 4). The cfDNA concentration had a moderate inverse correlation with CD4 count (-0.43 [95% CI: -0.68 to -0.10; p=0.011]) (Fig. 2A) and days to culture positivity 273 (-0.36 [95% CI: -0.64 to -0.0060; p=0.041]) (Fig S1), but no significant correlation with days of 274 anti-TB treatment, AFB smear score, or Alere urine LAM score (Table S3). The cfDNA 275 concentration was higher in patients with some treatment compared to treatment-naïve 276 277 patients (p=0.045) and in urine LAM-positive patients compared to urine LAM-negative patients 278 (p=0.0045), but was not significantly different in patients grouped by HIV status, CD4 count, 279 culture result, smear result, or gender (Fig. 2B).

		Median (IQR) <sup>a</sup>	Range <sup>a</sup>
		[copies in 10 mL urine]	[copies in 10 mL urine]
Total		146 (17 – 1092)	1.4 - 28044
TB treatment	Treatment-naïve	57 (7.6 – 557)	1.4 - 28044
status <sup>b</sup>	Some treatment	796 (104 – 2111)	3.9 - 18543
Alere urine LAM	Positive	796 (119 – 2851)	28 – 28044
result <sup>c</sup>	Negative	39 (4.9 – 404)	1.4 - 5021

### **Table 4: Detected concentrations of TB-specific urine cfDNA.**

<sup>a</sup> Concentration for each sample is given as copies of single-stranded DNA in 10 mL urine, which
 was calculated based on the mean across n=3 technical replicates.

<sup>b</sup> Detected cfDNA concentration was higher in patients with some treatment (Mann-Whitney,

284 p=0.045).

<sup>c</sup> Detected cfDNA concentration was higher in patients with a positive urine LAM result (Mann-

286 Whitney, p=0.0045).





288 Fig. 2: Detected concentrations of TB-specific urine cfDNA. (A) Concentration of TB cfDNA 289 detected in each participant's urine, stratified by HIV status and ranked by CD4 count. There was a moderate inverse correlation between CD4 count and detected TB cfDNA concentration 290 (Spearman's r = -0.43 [95% CI: -0.68 to -0.10], p = 0.011), but TB cfDNA could be detected 291 regardless of HIV status and CD4 count. Each dot represents one of three replicates processed 292 293 on different days for each sample. Note that dots representing replicates with similar detected concentrations may overlap. Replicates called as positive are shown in blue and replicates 294 called as negative are shown in red. The dashed line indicates the 1 copy per 10 mL threshold 295 296 used to define positive replicates. The legend below the plot indicates cfDNA detection status by replicate (considered positive if ≥1 copy of single-stranded DNA was detected with melt 297 298 temperature matching that of the expected IS6110 amplicon) and by sample (considered

positive if  $\ge 2$  of 3 replicates were positive). **(B)** Comparison of detected TB cfDNA concentration across groups (bars indicate median and IQR of sample means of cfDNA-positive samples). The detected TB cfDNA concentration was significantly higher in patients with some treatment compared to treatment-naïve patients, and in LAM-positive patients compared to LAMnegative patients (\* indicates Mann-Whitney P < 0.05; \*\* indicates Mann-Whitney P < 0.01), but was not affected by HIV status, CD4 count, culture result, smear result, or gender (ns indicates not significant). See Table S4 for calculated P-values for each comparison.

### 306 DISCUSSION

307 **Improved detection of short cfDNA in urine using sequence-specific purification.** To maximize 308 sensitivity of TB urine cfDNA detection, it is essential to use methods designed to detect low concentrations of short fragments (6, 14, 15). Decreasing the minimum target length is 309 expected to improve cfDNA diagnostic sensitivity (8, 27–29). For example, decreasing PCR 310 amplicon length by a modest 10 bp (49 bp to 39 bp) led to more than 10-fold increase in 311 detected TB-specific cfDNA (29). Critically, in addition to amplifying short targets, sample 312 313 preparation methods must also extract short cfDNA from urine with high efficiency. Conventional silica-based DNA extraction methods have reduced recovery of short fragments 314 and are thus not optimal for urine cfDNA (30). 315

316 We aimed to increase the diagnostic sensitivity of TB urine cfDNA detection by improving 317 recovery of short cfDNA during the DNA extraction step. We developed a sequence-specific 318 purification method that uses hybridization capture probes immobilized on magnetic beads to extract short cfDNA with high analytical sensitivity. We have previously demonstrated that 319 sequence-specific purification improves recovery of short cfDNA fragments (25 – 150 bp) from 320 321 urine compared to alternate urine cfDNA extraction methods, including a protocol used for TB 322 urine cfDNA (31). In a recent paper detailing our sequence-specific purification method, we described its key features, provided a user-ready protocol, and thoroughly characterized its 323 324 analytical performance (24). In this study, our sequence-specific approach recovered nearly all 325 target-specific 50 bp positive control DNA (91.8% average recovery) and was in some clinical specimens able to detect down to a single copy of TB cfDNA in 10 mL urine. 326

## 327 Diagnostic accuracy and comparison to previous TB urine cfDNA studies. In this study, we

- 328 tested our sequence-specific TB cfDNA assay in clinical urine specimens for the first time. The
- sensitivity and specificity of our assay for diagnosis of active pulmonary TB were 84% and 100%,
- 330 respectively, the highest reported diagnostic accuracy of a TB cfDNA test. For comparison,
- 331 previous TB urine cfDNA studies are summarized in Table 5 (8–12). For a comprehensive review
- 332 of previous studies, refer to (14).

# 333 Table 5: Comparison to previous studies targeting urine cfDNA for pulmonary TB diagnosis.<sup>a</sup>

First author	Year	Year	Year	DNA	extraction	PCR amplicon	Effective urine volume	Proportion of smear-	Sensi	tivity	Specificity
		Method	Designed for short urine cfDNA?	length	analyzed⁵	negative participants <sup>c</sup>	HIV- negative patients	HIV- positive patients			
Cannas (8)	2008	Wizard silica resin	Claimed, but we have identified limitations (<35% recovery of ≤150 bp DNA) <sup>d</sup>	129/67 bp (nested)	0.35 mL	2/43	79% (34/43)	NA	100% (23/23)		
Peter (12) <sup>e</sup>	2012	Xpert cartridge	No	192 bp (Xpert)	NR	NR	8% (3/38)	NA	NA		
Fortún (13)	2014	NR	No	NR (AMTD)	NR	NR	18% (	5/28)	NA		
Bordelon (11)	2017	MagMAX silica beads	No	67 bp	0.1 – 0.5 mL	NR	0% (0	)/33)	0% (0/31)		
Labugger (9)	2017	Unspecified silica resin <sup>f</sup>	Claimed (33% recovery of 75 bp DNA) <sup>g</sup>	38 bp	1.6 mL	4/10	64% (7/11)	NA	100% (8/8)		
Patel (10)	2018	Unspecified silica resin <sup>f</sup>	Claimed (~50% recovery of gDNA) <sup>h</sup>	38 bp	NR	45/175	40% (36/90)	45% (38/84)	89% (210/237)		
Oreskovic (this study)		Sequence- specific purification	Yes (>90% recovery of 50 bp DNA)	40 bp	10 mL	30/49	73% (11/15)	88% (30/34)	100% (24/24)		

334 NR indicates not reported. NA indicates not applicable. Xpert indicates Xpert MTB/RIF assay

335 (Cepheid). AMTD indicates Amplified Mycobacterium Tuberculosis Direct Test (Gen-Probe).

336 gDNA indicates TB genomic DNA.

<sup>a</sup> Included studies specifically targeted urine cell-free DNA for pulmonary TB diagnosis. Studies

analyzing cell-associated DNA, plasma cfDNA, or EPTB were excluded. Studies targeting plasma

cfDNA were excluded here but reported 65%/93% (32), 29%/100% (32), and 45%/67% (33)

340 sensitivity/specificity.

<sup>b</sup> Calculated based on the urine input volume, elution volume, and PCR input volume.

<sup>c</sup> Given as proportion of TB-positive participants who had a negative sputum smear microscopy

343 result. cfDNA detection sensitivity may be lower in smear-negative patients compared to

- 344 smear-positive patients.
- <sup>d</sup> We found that the Wizard silica method had low recovery of short fragments (<35% for 40 –

150 bp) and was dependent on urine composition (*i.e.*, pH and non-target DNA concentration)

347 (31).

<sup>e</sup> Peter *et al.* tested both whole urine and the insoluble fraction of urine concentrated by

349 centrifugation. Only results from whole urine testing are listed here because cfDNA is expected

to be in the soluble fraction of centrifuged urine.

<sup>f</sup> Labugger *et al.* and Patel *et al.* used a silica resin-based method similar to that used by Cannas
 *et al.*, but did not specify the resin or binding buffer.

<sup>g</sup> Estimated based on reported average of 1.6 cycle delay for extraction calibration curves

compared to PCR calibration curves for genomic DNA and a 75 bp target.

<sup>355</sup> <sup>h</sup> Estimated based on reported approximate 1 cycle delay for extraction calibration curves

356 compared to PCR calibration curves for genomic DNA.

357 Prior studies showed potential for detection of TB-specific urine cfDNA in HIV-positive and HIV-

358 negative patients, but had variable sensitivity due to sample preparation and/or amplification

359 methods sub-optimal for short targets (6, 14, 15). Cannas *et al.* used an in-house silica resin

360 method (based on Promega Wizard DNA Purification Resin) reportedly designed to improve

binding of short cfDNA, but did not report its analytical performance (e.q., percent recovery) 361 362 (8). While the Wizard method improves upon conventional silica-based methods, our past 363 testing revealed limited recovery (<35%) of  $\leq$ 150 bp fragments (31). It was also highly 364 dependent on urine composition and is likely to fail in samples with high pH and/or low nontarget DNA concentrations (31). Labugger et al. and Patel et al. used a similar silica resin-based 365 method, but did not specify the resin or binding conditions (9, 10). It is possible that their 366 method suffers from similar limitations as the Wizard method used by Cannas et al., although 367 we could not experimentally verify this. They reported recoveries of approximately 30 – 50% 368 369 and limits of detection of 3 copies/mL (75 bp target) (9) and 1.25 copies/mL (TB gDNA 370 containing up to 42 target repeats) (10). Our sequence-specific purification method increases percent recovery by 2-fold or more and improves the limit of detection to  $\leq 0.5$  copies/mL of 50 371 bp cfDNA (positivity cutoff threshold of 0.1 copies/mL used here). Our method allows the full 372 volume eluted from a 10 mL urine extraction to be amplified in a single PCR well, maximizing 373 sensitivity for detection of low-concentration samples. 374

Past studies also enrolled few smear-negative participants, and thus have not tested the ability to detect urine cfDNA in individuals with paucibacillary TB who stand to benefit most from a non-sputum-based test. In particular, the most promising study by Cannas *et al.* included only 5% (2/43) smear-negative participants. Our results indicate that cfDNA detection sensitivity is higher in smear-positive compared to smear-negative individuals, so enrollment biased towards smear-positive participants may lead to an overestimation of assay sensitivity. In contrast, we demonstrated higher sensitivity while including 61% (30/49) smear-negative participants.

Although not directly tested here, an added benefit of our sequence-specific approach is that it may help ensure specificity by removing non-target DNA. Sequence-specific purification has been used to improve sensitivity of TB diagnosis from sputum by removing high concentrations of non-target DNA that can lead to downstream amplification inhibition (34), but has not been applied in urine where the primary advantage of non-target DNA removal would be to reduce the likelihood of downstream nonspecific amplification. Confirming specific amplification of short targets without the footprint for a fluorescent detection probe can be difficult, but the

21

added layer of specificity offered by sequence-specific purification may aid in overcoming thischallenge.

391 **Comparison to existing rapid TB tests.** Our urine cfDNA assay has the potential to diagnose TB in individuals who may be missed by other rapid tests (e.g., smear microscopy, urine LAM). We 392 detected TB-specific cfDNA in the urine of all smear-positive and LAM-positive patients. 393 394 Importantly, sensitivity remained high in both smear-negative (76.0%) and LAM-negative 395 (76.5%) patients. The target product profile for a rapid biomarker-based non-sputum-based TB 396 test outlines the optimal requirements for pulmonary TB in adults as ≥98% for smear-positive TB,  $\geq$ 68% for smear-negative TB, and  $\geq$ 80% sensitivity for HIV-associated TB (5). Our results 397 suggest that, by employing an optimized extraction method with demonstrated high efficiency 398 399 for short fragments, urine cfDNA-based assays have the potential to achieve sufficient 400 sensitivity to meet these criteria and improve diagnostic accuracy compared to smear microscopy. 401

402 Unlike urine LAM tests, which have insufficient sensitivity, particularly in HIV-negative 403 individuals (35), cfDNA tests have the potential to diagnose TB regardless of HIV status and CD4 count. We observed slightly higher sensitivity in HIV-positive (88.2%) compared to HIV-negative 404 405 (73.3%) patients, but the difference was non-significant and the number of HIV-negative patients was small. Despite a moderate inverse correlation between CD4 count and detected 406 407 TB-specific cfDNA concentration, there was no difference in sensitivity for HIV-positive patients with CD4 counts of  $\leq 200$  compared to > 200 cells/mm<sup>3</sup>. In contrast, the commercially-available 408 409 Alere Determine TB LAM test has 42% pooled sensitivity in HIV-positive individuals, with sensitivity inversely proportional to CD4 cell count (36). The WHO only recommends its use in 410 people living with HIV but not as a general screening test for TB (37). Ongoing efforts aim to 411 412 improve urine LAM detection sensitivity. The Fujifilm SILVAMP TB LAM test improves sensitivity relative to Alere LAM in both HIV-positive (70% vs. 42%) and HIV-negative (53% vs. 11%) 413 414 individuals (38, 39). As antigen-based tests, however, LAM assays may not be able to achieve 415 the sensitivity afforded by nucleic acid amplification tests.

416 **Contributions to evidence for urine cfDNA as a biomarker for TB.** To date, usefulness of urine 417 cfDNA as a biomarker for TB has been limited, in part due to inconsistent methods and results

418 in previous TB urine cfDNA studies. Our study contributes to the evidence for urine cfDNA as a 419 TB biomarker in two ways: 1) demonstration of the feasibility of high sensitivity and specificity 420 with optimal pre-analytical methods and 2) development of a reliable, guantifiable method to 421 further study TB urine cfDNA. Previous TB urine cfDNA studies have focused on measuring 422 diagnostic accuracy, and have mostly neglected to report TB urine cfDNA concentrations. Labugger et al. measured concentrations for a limited number of treatment-naïve individuals 423 424 (n=7), which ranged from 1 - 41 copies/mL (median 6.5 copies/mL) (9). Here, we quantified TBspecific cfDNA to better estimate the clinical range (<1 - 2804 copies/mL; median 14.6 425 copies/mL), and have conducted analyses to determine which variables correlate with cfDNA 426 427 concentration. We found that cfDNA concentration was higher in LAM-positive patients 428 compared to LAM-negative patients, but LAM result did not affect cfDNA sensitivity. We detected cfDNA in all patients who had recently initiated TB treatment, with a higher 429 concentration compared to treatment-naïve patients, supporting the possibility of using cfDNA 430 for treatment monitoring as suggested previously (9). Upon initiation of a successful treatment 431 regimen, cfDNA concentration may temporarily increase, followed by a slow decline as the 432 infection is cleared (9). Our study did not show a correlation between days of treatment and 433 434 cfDNA concentration, but only included participants with  $\leq 3$  days of treatment and did not 435 monitor individual participants over time.

436 Although cfDNA was detectable regardless of HIV status or CD4 count, the detected 437 concentration had a moderate inverse correlation with CD4 count. We also found that cfDNA 438 concentration had a moderate inverse correlation with days to culture positivity, suggesting 439 that levels of excreted cfDNA may be related to bacterial burden. We observed no correlation 440 with AFB sputum smear score or Alere urine LAM score, but the sample sizes for these analyses were low. We anticipate that our assay can be used to continue to study TB urine cfDNA trends 441 across sub-groups and answer important unresolved questions regarding optimal sample 442 collection techniques, processing methods, and storage conditions that have been the focus of 443 recent work (40–42). As a caveat, the cfDNA concentrations measured by our assay may be 444 445 confounded by the variable copy number of IS6110 (0–25 copies) (25) and by differences in

participants' hydration statuses. In the future, strain typing and normalizing cfDNA 446 447 concentration to urine creatinine may help better elucidate trends in cfDNA concentration. Study limitations and future work. TB symptoms were required in addition to a positive Xpert 448 result for the TB case definition to reduce the risk of a false-positive Xpert result, but it is 449 450 possible that some could still have occurred. Using the strictest TB-positive criteria, requiring 451 both positive Xpert and positive culture, would result in a non-significant increase in cfDNA 452 sensitivity (88%). Several TB-positive, cfDNA-negative samples (false negatives) narrowly missed 453 the cfDNA positivity cutoff, suggesting the opportunity for future improvement in clinical 454 sensitivity. We are currently pursuing two approaches to further improve our assay's ability to detect low cfDNA concentrations: a reduction in PCR target length (to 25 bp using an ultrashort 455 PCR design described in (31)) and multiplexing to target multiple genomic regions. Multiplexing 456 457 will have the additional benefit of improving inclusivity by enabling detection of TB strains lacking IS6110. 458

459 This study serves as a valuable demonstration of the feasibility of our sequence-specific 460 approach, but the sample size and scope were limited. Future studies will seek to further validate our assay with larger sample sizes (including more HIV-negative participants and 461 negative controls) and expanded populations, specifically those underserved by current rapid 462 sputum-based tests (including children and patients with EPTB). TB-specific cfDNA has been 463 detected in the urine (13) and plasma (43–45) of individuals with EPTB, including a case study of 464 a child with tubercular otitis media (46), but there have not yet been any prospective studies in 465 children. Our assay also currently requires a trained user and laboratory equipment. In the 466 467 future, we aim to simplify our lab-based test into a format more suitable for use in resourcelimited settings. 468

Conclusion. Sequence-specific purification improves recovery of short urine cfDNA and increases the sensitivity of TB diagnosis from urine cfDNA. Our assay has the highest reported accuracy of any TB urine cfDNA test to date and has the potential to enable urine-based TB diagnosis across sputum-scarce and paucibacillary populations. This study will lay the foundation for expanded clinical studies and future development of a rapid test. In addition,

24

our work serves as a valuable contribution to the clinical evidence for urine cfDNA as a
biomarker for TB. The ability to diagnose TB across key underserved populations (*e.g.*, children,
people living with HIV, individuals with EPTB) using urine samples would address an urgent
need that was identified as one of the highest priority gaps in TB diagnostics (5). A sensitive
urine-based test built upon the sequence-specific purification method described here could
significantly contribute to improving sample availability, expanding access to rapid TB diagnosis,
and controlling the TB epidemic.

#### 481 ACKNOWLEDGEMENTS

482 We are grateful to study participants for their contributions to this research. We thank the KwaZulu-Natal Department of Health and staff of Edendale Hospital for their partnership and 483 484 Norman D. Brault and James Lai for their contributions to the early development of the 485 sequence-specific purification method. Research reported in this publication was funded by the Bill and Melinda Gates Foundation under award number OPP1152864 and the National 486 487 Institute of Allergy and Infectious Diseases of the National Institutes of Health under award 488 number R21AI125975. The content is solely the responsibility of the authors and does not 489 necessarily represent the official views of the National Institutes of Health. This research was 490 funded in part by a 2018 CFAR developmental grant from the University of Washington/Fred Hutch Center for AIDS Research, an NIH-funded program under award number AI027757 which 491 492 is supported by the following NIH Institutes and Centers: NIAID, NCI, NIMH, NIDA, NICHD, 493 NHLBI, NIA, NIGMS, NIDDK. A.O. was supported by funding from the National Science 494 Foundation Graduate Research Fellowship Program. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. 495

#### 496 **REFERENCES**

497 1. World Health Organization. 2020. Global tuberculosis report 2020.

- 498 2. Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, Schumacher SG,
- 499 Ochodo EA, Pai M, Steingart KR. 2019. Xpert MTB/RIF and Xpert MTB/RIF Ultra for
- pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev2019:6.
- Detjen AK, DiNardo AR, Leyden J, Steingart KR, Menzies D, Schiller I, Dendukuri N,
   Mandalakas AM. 2015. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis
   in children: a systematic review and meta-analysis. Lancet Respir Med 3:451–61.
- Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger CM, Schumacher SG, Steingart KR.
   2018. Xpert MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.
- 507 Cochrane Database Syst Rev 2018:8.
- 508 5. World Health Organization. 2014. High-priority target product profiles for new
  509 tuberculosis diagnostics: report of a consensus meeting.
- Green C, Huggett JF, Talbot E, Mwaba P, Reither K, Zumla AI. 2009. Rapid diagnosis of
   tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid
   amplification methods. Lancet Infect Dis 9:505–511.
- 513 7. Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananév V, Bazin I,
   514 Garin A, Narimanov M, Knysh V, Melkonyan H, Umansky S, Lichtenstein A. 2000. Genetic
   515 analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA
   516 sequences from cells dying in an organism. Clin Chem 46:1078–84.
- Cannas A, Goletti D, Girardi E, Chiacchio T, Calvo L, Cuzzi G, Piacentini M, Melkonyan H,
   Umansky SR, Lauria FN, Ippolito G, Tomei LD. 2008. Mycobacterium tuberculosis DNA
   detection in soluble fraction of urine from pulmonary tuberculosis patients. Int J Tuberc
   Lung Dis 12:146–151.
- Labugger I, Heyckendorf J, Dees S, Häussinger E, Herzmann C, Kohl TA, Richter E, Rivera Milla E, Lange C. 2016. Detection of transrenal DNA for the diagnosis of pulmonary

523 tuberculosis and treatment monitoring. Infection 45:1–8.

- 10. Patel K, Nagel M, Wesolowski M, Dees S, Rivera-Milla E, Geldmacher C, Dheda K,
- 525 Hoelscher M, Labugger I. 2018. Evaluation of a Urine-Based Rapid Molecular Diagnostic
- 526 Test with Potential to Be Used at Point-of-Care for Pulmonary Tuberculosis: Cape Town
- 527 Cohort. J Mol Diagnostics 20:215–224.
- 528 11. Bordelon H, Ricks KM, Pask ME, Russ PK, Solinas F, Baglia ML, Short PA, Nel A, Blackburn
- J, Dheda K, Zamudio C, Cáceres T, Wright DW, Haselton FR, Pettit AC. 2017. Design and
- 530 use of mouse control DNA for DNA biomarker extraction and PCR detection from urine:
- 531 Application for transrenal Mycobacterium tuberculosis DNA detection. J Microbiol
- 532 Methods 136:65–70.
- Peter JG, Theron G, Muchinga TE, Govender U, Dheda K. 2012. The diagnostic accuracy of
  urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative
  or sputum scarce. PLoS One 7:1–8.
- Fortún J, Martín-Dá P, G ´ Omez-Mampaso E, Gonzá Lez-García A, Barbolla I, G ´ OmezGarcía I, Wikman P, Ortíz J, Navas E, Cuartero C, Gijón D, Gijón G, Moreno S. 2014. Extrapulmonary tuberculosis: differential aspects and role of 16S-rRNA in urine. Int J Tuberc
- 539 Lung Dis 18:478–485.
- 540 14. Leticia Fernández-Carballo B, Broger T, Wyss R, Banaei N. 2019. Towards the
- development of a cfDNA-based in-vitro diagnostic test for infectious diseases: A review
  of evidence for tuberculosis. J Clin Microbiol 57:e01234-18.
- 543 15. Marangu D, Devine B, John-Stewart G. 2015. Diagnostic accuracy of nucleic acid
  544 amplification tests in urine for pulmonary tuberculosis: A meta-analysis. Int J Tuberc Lung
  545 Dis 19:1339–47.
- Tsui NBY, Jiang P, Chow KCK, Su X, Leung TY, Sun H, Chan KCA, Chiu RWK, Lo YMD. 2012.
  High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end
  massively parallel sequencing. PLoS One 7:e48319.
- 549 17. Markus H, Zhao J, Contente-Cuomo T, Raupach E, Odenheimer-Bergman A, Connor S,

					. <i>.</i> . <i>..</i>	
550	Mcdonald BR	Hutchins F Mcgily	/erv M De la	Maza MC	Van Keuren-Jensen K	Pirrotte P
550		, $($ $($ $($ $($ $))$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $($ $)$ $()$		i iviuzu ivic,	Van Kearen Jensen K	, , , , , , , , , , , , , , , , , , , ,

- 551 Goel A, Becerra C, Von Hoff DD, Celinski SA, Hingorani P, Murtaza M. Sub-nucleosomal
- organization in urine cell-free DNA. bioRxiv https://doi.org/10.1101/696633.
- 18. Burnham P, Kim MS, Agbor-Enoh S, Luikart H, Valantine HA, Khush KK, De Vlaminck I.
- 2016. Single-stranded DNA library preparation uncovers the origin and diversity of
  ultrashort cell-free DNA in plasma. Sci Rep 6:27859.
- Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. 2016. Cell-free DNA Comprises an in
  Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell 164:57–68.
- 558 20. Sanchez C, Snyder MW, Tanos R, Shendure J, Thierry AR. 2018. New insights into
- structural features and optimal detection of circulating tumor DNA determined by singlestrand DNA analysis. npj Genomic Med 3:31.
- Burnham P, Dadhania D, Heyang M, Chen F, Westblade LF, Suthanthiran M, Lee JR, De
  Vlaminck I. 2018. Urinary cell-free DNA is a versatile analyte for monitoring infections of
  the urinary tract. Nat Commun 9:2412.
- 22. Cheng THTT, Jiang P, Tam JCWW, Sun X, Lee W-S, Yu SCYY, Teoh JYCC, Chiu PKFF, Ng C-F,
- 565 Chow K-M, Szeto C-C, Chan KCACA, Chiu RWKK, Dennis Lo YM, Lo YMD. 2017.
- 566 Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation 567 of urinary cfDNA. Clin Biochem 50:496–501.
- Yao W, Mei C, Nan X, Hui L. 2016. Evaluation and comparison of in vitro degradation
  kinetics of DNA in serum, urine and saliva: A qualitative study. Gene 590:142–148.
- 570 24. Oreskovic A, Lutz B. 2021. Ultrasensitive hybridization capture: reliable detection of <1</li>
  571 copy/mL short cell-free DNA from large-volume urine samples. PLoS One (revised
  572 manuscript under review.
- 573 25. del Carmen Menéndez M, Samper S, Otal I, García MJ. 2012. IS6110 the Double-Edged
  574 Passenger, p. 59–88. *In* Cardona, P-J (ed.), Understanding Tuberculosis Deciphering the
  575 Secret Life of the Bacilli. InTech Open.
- 576 26. Hellyer TJ, Desjardin LE, Assaf MK, Bates JH, Cave MD, Eisenach KD. 1996. Specificity of

577 IS6110-based amplification assays for Mycobacterium tuberculosis complex. J Clin
578 Microbiol 34:2843–2846.

- Su Y-H, Wang M, Block TM, Landt O, Botezatu I, Serdyuk O, Lichtenstein A, Melkonyan H,
  Tomei LD, Umansky S. 2004. Transrenal DNA as a diagnostic tool: important technical
  notes. Ann N Y Acad Sci 1022:81–9.
- 582 28. Shekhtman EM, Anne K, Melkonyan HS, Robbins DJ, Warsof SL, Umansky SR. 2009.
  583 Optimization of transrenal DNA analysis: detection of fetal DNA in maternal urine. Clin
  584 Chem 55:723–9.
- Melkonyan HS, Feaver WJ, Meyer E, Scheinker V, Shekhtman EM, Xin ZH, Umansky SR.
  2008. Transrenal Nucleic Acids: From Proof of Principle to Clinical Tests. Ann N Y Acad Sci
  1137:73–81.
- 58830.Boom R, Sol C, MM S, Jansen C, Wertheim-van Dillen P, van der Noordaa J. 1990. Rapid589and Simple Method for Purification of Nucleic Acids. J Clin Microbiol 28:495–503.
- S90 31. Oreskovic A, Brault ND, Panpradist N, Lai JJ, Lutz BR. 2019. Analytical Comparison of
  Methods for Extraction of Short Cell-Free DNA from Urine. J Mol Diagnostics 21:1067–
  1078.
- 32. Ushio R, Yamamoto M, Nakashima K, Watanabe H, Nagai K, Shibata Y, Tashiro K,
  Tsukahara T, Nagakura H, Horita N, Sato T, Shinkai M, Kudo M, Ueda A, Kaneko T. 2016.
  Digital PCR assay detection of circulating Mycobacterium tuberculosis DNA in pulmonary
  tuberculosis patient plasma. Tuberculosis 99:47–53.

Reed JL, Basu D, Butzler MA, McFall SM. 2017. XtracTB Assay, a Mycobacterium
tuberculosis molecular screening test with sensitivity approaching culture. Sci Rep
7:3653.

35. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. 2011. Diagnosing tuberculosis

with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J
38:1398–1405.

- Bjerrum S, Schiller I, Dendukuri N, Kohli M, Nathavitharana RR, Zwerling AA, Denkinger
  CM, Steingart KR, Shah M. 2019. Lateral flow urine lipoarabinomannan assay for
  detecting active tuberculosis in people living with HIV. Cochrane Database Syst Rev
  2019:10.
- World Health Organization. 2019. Lateral flow urine lipoarabinomannan assay (LF-LAM)
  for the diagnosis of active tuberculosis in people living with HIV: Policy update (2019).
- 38. Broger T, Nicol MP, Sigal GB, Gotuzzo E, Zimmer AJ, Surtie S, Caceres-Nakiche T,
- 613 Mantsoki A, Reipold EI, Székely R, Tsionsky M, van Heerden J, Plisova T, Chikamatsu K,
- Lowary TL, Pinter A, Mitarai S, Moreau E, Schumacher SG, Denkinger CM. 2020.
- Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative
   outpatients. J Clin Invest 130:5756–5764.
- 39. Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Ivanova Reipold E, Ward A, Barr DA,
- Macé A, Trollip A, Burton R, Ongarello S, Pinter A, Lowary TL, Boehme C, Nicol MP,
- 619 Meintjes G, Denkinger CM. 2019. Novel lipoarabinomannan point-of-care tuberculosis
- test for people with HIV: a diagnostic accuracy study. Lancet Infect Dis 19:852–861.
- 40. Murugesan K, Hogan CA, Palmer Z, Reeve B, Theron G, Andama A, Somoskovi A,
- 622 Steadman A, Madan D, Andrews J, Croda J, Sahoo MK, Cattamanchi A, Pinsky BA, Banaei
- N. 2019. Investigation of preanalytical variables impacting pathogen cell-free DNA in
  blood and urine. J Clin Microbiol 57:e00782-19.
- 41. Lee EY, Lee E-J, Yoon H, Lee DH, Kim KH. 2020. Comparison of Four Commercial Kits for
  Isolation of Urinary Cell-Free DNA and Sample Storage Conditions. Diagnostics 10:234.
- 42. Augustus E, Van Casteren K, Sorber L, van Dam P, Roeyen G, Peeters M, Vorsters A,
- 628 Wouters A, Raskin J, Rolfo C, Zwaenepoel K, Pauwels P. 2020. The art of obtaining a high 629 yield of cell-free DNA from urine. PLoS One 15:e0231058.
- 43. Yamamoto M, Ushio R, Watanabe H, Tachibana T, Tanaka M, Yokose T, Tsukiji J,

631		Nakajima H, Kaneko T. 2018. Detection of Mycobacterium tuberculosis-derived DNA in
632		circulating cell-free DNA from a patient with disseminated infection using digital PCR. Int
633		J Infect Dis 66:80–82.
634	44.	Lyu L, Li Z, Pan L, Jia H, Sun Q, Liu Q, Zhang Z. 2020. Evaluation of digital PCR assay in
635		detection of M.tuberculosis IS6110 and IS1081 in tuberculosis patients plasma. BMC
636		Infect Dis 20:657.
637	45.	Yang J, Han X, Liu A, Bai X, Xu C, Bao F, Feng S, Tao L, Ma M, Peng Y. 2017. Use of Digital
638		Droplet PCR to Detect Mycobacterium tuberculosis DNA in Whole Blood-Derived DNA
639		Samples from Patients with Pulmonary and Extrapulmonary Tuberculosis. Front Cell
640		Infect Microbiol 7:369.
641	46.	Petrucci R, Lombardi G, Corsini I, Visciotti F, Pirodda A, Cazzato S, Landini MP, Dal Monte
642		P. 2015. Use of transrenal DNA for the diagnosis of extrapulmonary tuberculosis in
643		children: a case of tubercular otitis media. J Clin Microbiol 53:336–8.
644		